Gathering the record
Relay is organizing the evidence and source boundaries.
Erythropoietin-derived tissue-protective peptide
An experimental peptide, also called cibinetide, studied mainly for nerve problems and related pain.
Evidence is explained by question. Dosing references show their own check dates.
60-second overview
Why people look into it, what studies found, and what is still unknown.
Educational information only. Evidence reviewed through July 31, 2026. Published studies, sponsor announcements, and trials without results are labeled separately. Evidence gaps apply to the specific finding beside them.
Research questions
Each label shows how much evidence supports that question.
What studies show
Randomized Phase 2 studies in sarcoidosis-associated small-fiber neuropathy reported nerve-fiber and symptom findings over approximately four weeks.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Risks & unknowns
Small trials did not identify erythropoietic effects expected from full EPO, but study size and duration are insufficient for uncommon or longer-term risks.
Controlled human evidenceReported events depend on population, formulation, route, exposure, comparator, and study size.
Open sourceSmall trials did not identify erythropoietic effects expected from full EPO, but study size and duration are insufficient for uncommon or longer-term risks.
Controlled human evidenceLow-frequency estimates are sensitive to sample size, follow-up, ascertainment, formulation, and population.
Open sourceRelay has not verified which side effects led people to stop treatment in studies.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
Relay has not verified a compound-specific warning summary for this profile.
Evidence boundaryInvestigational; no FDA-approved cibinetide product. Whether benefits reproduce in larger, longer trials with clinically decisive endpoints and a fully characterized safety profile.
This profile does not contain verified, product-specific emergency instructions.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Dosing references
Each table labels its source and applies only to the named route, product, or study. An online example or community report is not an approved dose.
Amounts reported in a human study. A studied amount is not automatically an approved dose or a recommendation for an individual.
A blinded, placebo-controlled trial studied sarcoidosis-associated small-fiber nerve damage.
| Stage / period | Amount in source | Frequency |
|---|---|---|
| 28 days | 4 mg | Daily |
This is a disease-specific experimental regimen, not an established general nerve-recovery protocol. The small trial and limited follow-up cannot define uncommon or long-term risks.
ARA-290 · sarcoidosis small-fiber neuropathy trial Full text · Rationale for dose selection and Study designThis reference checked Oct 20, 2026. The full-profile review date is shown at the top.This source does not establish a mixing volume or storage period for independently sourced powder. Use formulation-specific instructions; the study amount alone is not a reconstitution recipe.
Concentration = total mass ÷ final volume. The calculator performs user-entered math; it does not choose a dose or diluent.
Open concentration calculatorStarting dose: the amount used at the beginning of the named label schedule or trial.
Maintenance: the ongoing amount described by that product label.
Trial target: the amount assigned to a study group. Different groups may stop increasing at different targets.
A randomized, blinded trial investigated cibinetide in adults with sarcoidosis-associated small-fiber neuropathy, measuring symptoms and function over a short treatment window.
Population: Adults with sarcoidosis-associated small-fiber neuropathy
Design: Randomized double-blind placebo-controlled trial
Mechanisms
The 11-amino-acid peptide targets the innate repair receptor complex proposed to include EPOR and CD131. Small controlled studies report corneal-nerve and symptom signals in selected neuropathy populations.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Research reference
A reference for the studies, populations, and routes behind this profile.
Controlled early human research in small-fiber neuropathy and related tissue-injury questions.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Whether benefits reproduce in larger, longer trials with clinically decisive endpoints and a fully characterized safety profile.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The study was small, short, and limited to a specialized neuropathy population. Signals in symptoms or nerve measures require larger confirmation and do not establish effects for unrelated pain, injury, or recovery questions. Amounts shown describe cited research exposure—not a dosage recommendation.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Randomized double-blind placebo-controlled trial
Adults with sarcoidosis-associated small-fiber neuropathy
A randomized placebo-controlled study reported symptom and functional signals in sarcoidosis-associated small-fiber neuropathy.
Study administration: Not stated in the current record.
Limitations: Small, short, indication-specific study.
Randomized double-blind placebo-controlled dose-ranging trial
Adults with painful sarcoid neuropathy
A dose-ranging randomized study reported corneal nerve-fiber changes and symptom associations.
Study administration: Not stated in the current record.
Limitations: Short study and specialized surrogate endpoint; requires larger confirmation.
Randomized controlled trial
Adults with diabetic macular edema
Endpoints were not fully described in the current record.
A 12-week controlled study explored ocular and systemic outcomes.
Study administration: Not stated in the current record.
Limitations: Exploratory findings across multiple endpoints.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 24136731
PMID 27965214
PMID 32587976